Patent

1. A method for reducing a tumor size in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one strain of Neospora caninum , wherein said at least one strain of Neospora caninum is at a tachyzoite stage.

2. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is a wild type strain.

3. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is a mutant strain characterized by an over-expression of GRA15 protein, and/or by an under-expression of ROP16 protein.

4. The method according to claim 1 , wherein said tumor is a solid tumor.

5. The method according to claim 1 , wherein said tumor is an ovarian cancer, pancreatic cancer or melanoma.

6. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is comprised in a composition in association with an excipient.

7. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is comprised in a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.

8. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is comprised in a vaccine composition.

9. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is comprised in a vaccine composition comprising an adjuvant.

10. The method according to claim 1 , wherein said at least one strain of Neospora caninum at a tachyzoite stage is administered to the subject via subcutaneous, intradermal or intratumoral routes.

11. The method according to claim 1 , wherein the therapeutically effective amount of Neospora caninum at a tachyzoite stage administered to the subject is ranging from about 10 4 to about 10 11 cells.